Position: Board member since 2014.

Education: Ph.D. in Genetics from Umeå University.

Experience: Former head of Life Science Investments at Industrifonden. He has more than 25 years’ experience from the pharma and biotech industry in executive positions at KabiGen, Symbicom AB, AstraZeneca AB, Karolinska Development AB and BioVitrum AB and as CEO for Arexis AB.

Other assignments: Member of the Board of InDex Pharmaceuticals AB and Medivir aktiebolag. Chairman of the Board of and Sixera Pharma AB,QureTech Bio AB and Ignitus AB.

Position: Board member since 2017.

Education: Master of Laws (LL.M.) from Uppsala University.

Experience: Experience: More than 20 years’ experience as a business lawyer, focusing entirely on advising clients within the life sciences industry on matters of commercial and corporate law. Previous work experience includes law firms Mannheimer Swartling, Lindahl and Bird & Bird. Since 2006 working for his own company IARU.

Other assignments: Member of the Board of Xspray Pharma AB (publ) and IARU Institutet för Affärsjuridisk Rådgivning i Uppsala AB.

Position: Board member since 2021.

Education: Master in Finance and Business Administration from Stockholm School of Economics.

Experience: More than 20 years of experience within asset management and equity markets from SEB, Nordea, Odin Funds and Neonet Securities. Entrepreneurial experience from building and running Nordic Investor Services, an advisory consultant within global corporate governance, since 2002.

Other assignments: Chairman of the Board in Factoringgruppen AB and Caroline Svedbom AB. Board member of Rejlers AB (publ), Stendörren Fastigheter AB (publ) and Occlutech AG.

Position: Board member since 2022.

Education: Ph.D. in Molecular Neurobiology and Master of Science in Biomedicine. Both from Karolinska Institutet.

Experience: Currently Partner and Co-Head at Trill Impact Ventures. Previous experience includes the roles of Head of life science at Industrifonden, Vice President, Strategy and Ventures at Gambro, and management consulting at Boston Consulting Group in Stockholm and New York.

Other assignments: Board member in Emerging Health Ventures I AB and serves on the board of Stockholms Sjukhem.

Position: Board member since 2016.

Education: Pharmacist, Ph.D of Pharmacy (pharma-cognosy), Adjunct Professor at Uppsala University.

Experience: Former Head of pharmacology at Pharmacia & Upjohn; VP clinical trials Quintiles Europe, CEO of Quintiles Scandinavia. Chairman of Aprea Therapeutics AB, Denator AB and Aprea Personal AB. Board member of Swedish Match AB, SOBI AB, Recipharm AB, Smartfish AB, Moberg Pharma AB, TFS Trial Form Support Internatio-nal AB, Apotek Produktion & Laboratorier AB and Industrifonden. Chairman Bionor Pharma AS and Chairman i BioArctic AB.

Other assignments: Chairman Index Pharmaceutical Holding AB. CEO and Board member in Rolfsen Consulting AB. Partner in Serendipity Partners.

Position: Board member since 2014.

Education: MD. Ph.D. Gastroenterologist and Internal Medicine and Hepatology from Karolinska Institutet.

Experience: 27 years of Clinical experience. Consultant at AstraZeneca and former VP at Novartis. Innovated the modern principles for H. pylori eradication therapy, currently state-of-the-art.

Other assignments: Chair of the Board of PetoMaj Invest AB, Chair of the Board of Cinclus Pharma AG.

Position: Board member since 2016.

Education: Master of Medical Sciences and Clinical Drug Development from Uppsala University.

Experience: More than 15 years experience from drug development and medical affairs within the pharmaceutical industry. He has held a broad spectrum of positions within clinical development, pharmacovigilance, quality assurance and medical affairs at Pfizer, Ipsen, Shire and Novartis. Currently Medical Director for Northern Europe at PTC Therapeutics.

Other assignments: Member of the Board in Regulus Pharma Fas 1 AB.